Medpace Holdings, Inc. $MEDP Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lowered its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 37,700 shares of the company’s stock after selling 651 shares during the quarter. Oppenheimer Asset Management Inc. owned about 0.13% of Medpace worth $11,833,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Geneos Wealth Management Inc. lifted its holdings in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. Brooklyn Investment Group lifted its holdings in Medpace by 244.8% in the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock valued at $30,000 after acquiring an additional 71 shares during the last quarter. Whittier Trust Co. lifted its holdings in Medpace by 47.3% in the 1st quarter. Whittier Trust Co. now owns 109 shares of the company’s stock valued at $33,000 after acquiring an additional 35 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Medpace in the 1st quarter valued at about $60,000. Finally, IFP Advisors Inc lifted its holdings in Medpace by 223.3% in the 2nd quarter. IFP Advisors Inc now owns 194 shares of the company’s stock valued at $61,000 after acquiring an additional 134 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Medpace

In other news, VP Susan E. Burwig sold 10,000 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total value of $4,800,000.00. Following the completion of the sale, the vice president directly owned 57,500 shares of the company’s stock, valued at approximately $27,600,000. This represents a 14.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO August J. Troendle sold 36,196 shares of the stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $475.90, for a total value of $17,225,676.40. Following the completion of the sale, the chief executive officer directly owned 925,799 shares of the company’s stock, valued at $440,587,744.10. This represents a 3.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 48,478 shares of company stock worth $23,093,073 over the last 90 days. Insiders own 20.30% of the company’s stock.

Medpace Stock Performance

NASDAQ:MEDP opened at $605.20 on Monday. The stock’s 50 day moving average price is $503.13 and its 200 day moving average price is $392.69. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $625.00. The company has a market capitalization of $17.05 billion, a P/E ratio of 42.32, a P/E/G ratio of 3.58 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating the consensus estimate of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. During the same quarter last year, the company posted $3.01 earnings per share. The company’s revenue for the quarter was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a report on Saturday. Rothschild & Co Redburn downgraded Medpace from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $342.00 to $474.00 in a report on Wednesday, September 3rd. Truist Financial raised their price target on shares of Medpace from $298.00 to $436.00 and gave the stock a “hold” rating in a report on Wednesday, July 23rd. UBS Group lowered shares of Medpace from a “neutral” rating to a “sell” rating and upped their price objective for the company from $300.00 to $305.00 in a research note on Tuesday, July 29th. Finally, Zacks Research lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 22nd. Two research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $464.00.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.